Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Trials begin of VNS (vagus nerve stimulator) in obesity and Alzheimer's:

This article was originally published in Clinica

Executive Summary

Researchers have carried out the first human implants in studies to assess Cyberonics' vagus nerve stimulator as a treatment for two new indications - Alzheimer's disease and obesity. The NeuroCybernetic Prosthesis, which is already FDA-approved for treating epilepsy, was last month implanted in the first of six patients, as part of the first phase of a US study to assess the device in people with obesity. The Houston, Texas-based company said that the first of 10 Alzheimer's patients scheduled to take part in a pilot study in Sweden also received the device last month.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT076877

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel